The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by …

Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate
inflammatory pathways by blocking one or more JAK receptors, and are increasingly being …

The inflammatory diseases ulcerative colitis and Crohn's disease constitute the two main
forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing …

Introduction: Current available treatments for inflammatory bowel disease (IBD) have some
limitations and new options are needed. Several new molecules are being tested for the …

The current treatment options for inflammatory bowel disease (IBD) include
aminosalicylates, immunosuppressives, corticosteroids, and monoclonal antibodies to tumor …

Although development of biologics has importantly improved the effectiveness in inducing
and maintaining remission in inflammatory bowel disease (IBD), biologic therapies still have …

In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of
ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC …

In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases
(IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus …